VEGFR
VEGFR(血管内皮生长因子受体)
VEGFR are receptors for vascular endothelial growth factor and belong to receptor tyrosine kinases.
VEGFR 相关产品(193)
- GC37773TG 100801 HydrochlorideCAS: 1018069-81-2
TG 100801 Hydrochloride 是TG 100572的前药,通过去酯化产生TG 100572,开发用来治疗年龄相关的黄斑变性。TG 100572是多靶点激酶抑制剂,抑制受体酪氨酸激酶 (receptor tyrosine kinases) 和Src激酶 (Src kinases); 对VEGFR1,VEGFR2,FGFR1,FGFR2,PDGFRβ,Fgr,Fyn,Hck,Lck,Lyn,Src,Yes 的 IC50 值分别为2,7,2,16,13,5,0.5,6,0.1,0.4,1,0.2。
- GC37808Toceranib phosphateCAS: 874819-74-6纯度: >98.00%
A multi-targeted receptor tyrosine kinase inhibitor
- GC39314Tyrphostin AG1433CAS: 168835-90-3纯度: >99.00%
Tyrphostin AG1433 (AG1433, SU1433) is a selective platelet-derived growth factor receptor β (PDGFRβ) and vascular endothelial growth factor receptor 2 (VEGFR-2, Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively.
- GC43885HypothemycinCAS: 76958-67-3纯度: >95.00%
A resorcylic acid lactone polyketide with diverse biological activities
- GC45677Anlotinib (hydrochloride)CAS: 1058157-76-8纯度: >95.00%
A neuropeptide with diverse biological activities
- GC45754Lenvatinib-d4CAS: 2264050-65-7纯度: >99.00%
Lenvatinib-d4 (E7080-d4) 是氘标记的 Lenvatinib。 Lenvatinib (E7080) 是一种口服的多靶点酪氨酸激酶抑制剂,可抑制 VEGFR1-3、FGFR1-4、PDGFR、KIT 和 RET,显示出有效的抗肿瘤活性。
- GC45828Ponatinib-d8CAS: 1562993-37-6纯度: >99.00%
An internal standard for the quantification of ponatinib
- GC48118Sunitinib-d10CAS: 1126721-82-1纯度: >99.00%
An internal standard for the quantification of sunitinib
- GC49686N-desmethyl Regorafenib N-oxideCAS: 835621-12-0纯度: >90.00%
An active metabolite of regorafenib
- GC60283Pentagamavunon-1CAS: 27060-70-4纯度: >99.50%
Pentagamavunon-1 (PGV-1) 是Curcumin 的类似物,具有口服活性,通过多个机制诱导凋亡信号,如抑制COX-2 和 VEGF。Pentagamavunon-1 (PGV-1) 可抑制 NF-κB 的激活。
- GC60365TIE-2/VEGFR-2 kinase-IN-1CAS: 453590-24-4纯度: >99.50%
TIE-2/VEGFR-2 kinase-IN-1 用于合成 TIE-2 或者 VEGFR-2 抑制剂,从专利 WO2003022852 中获得,例 14。TIE-2/VEGFR-2 kinase-IN-1 用于研究不适当的血管生成相关疾病。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC37773 | TG 100801 Hydrochloride | 1018069-81-2 | - | |
TG 100801 Hydrochloride 是TG 100572的前药,通过去酯化产生TG 100572,开发用来治疗年龄相关的黄斑变性。TG 100572是多靶点激酶抑制剂,抑制受体酪氨酸激酶 (receptor tyrosine kinases) 和Src激酶 (Src kinases); 对VEGFR1,VEGFR2,FGFR1,FGFR2,PDGFRβ,Fgr,Fyn,Hck,Lck,Lyn,Src,Yes 的 IC50 值分别为2,7,2,16,13,5,0.5,6,0.1,0.4,1,0.2。 | ||||
| GC37808 | Toceranib phosphate | 874819-74-6 | >98.00% | |
A multi-targeted receptor tyrosine kinase inhibitor | ||||
| GC37886 | Vandetanib trifluoroacetate | 338992-53-3 | - | |
A multi-kinase inhibitor | ||||
| GC37933 | WHI-P180 hydrochloride | 153437-55-9 | - | |
A multi-kinase inhibitor | ||||
| GC38380 | Vorolanib | 1013920-15-4 | >99.50% / >98.00% | |
Vorolanib(X-82;CM082)是一种具口服活性的血管内皮生长因子受体(VEGFR)和血小板衍生生长因子受体(PDGFR)的多激酶双重抑制剂,IC 50 值分别为0.052μM、0.26 μM。 | ||||
| GC38519 | Ilorasertib hydrochloride | 1847485-91-9 | >98.50% | |
A multi-kinase inhibitor | ||||
| GC38575 | CP-547632 hydrochloride | 252003-71-7 | >98.00% | |
A potent inhibitor of VEGFR2 and bFGF | ||||
| GC39314 | Tyrphostin AG1433 | 168835-90-3 | >99.00% | |
Tyrphostin AG1433 (AG1433, SU1433) is a selective platelet-derived growth factor receptor β (PDGFRβ) and vascular endothelial growth factor receptor 2 (VEGFR-2, Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively. | ||||
| GC40755 | SU 5214 | 186611-04-1 | >98.00% | |
A 3-heteroaryl-2-indoline | ||||
| GC43885 | Hypothemycin | 76958-67-3 | >95.00% | |
A resorcylic acid lactone polyketide with diverse biological activities | ||||
| GC44474 | NVP-AEW541 (hydrochloride) | 2320261-63-8 | >98.00% | |
An IGF-1R inhibitor | ||||
| GC44958 | SU 5205 | 3476-86-6 | >98.00% | |
An inhibitor of VEGFR2 | ||||
| GC45677 | Anlotinib (hydrochloride) | 1058157-76-8 | >95.00% | |
A neuropeptide with diverse biological activities | ||||
| GC45754 | Lenvatinib-d4 | 2264050-65-7 | >99.00% | |
Lenvatinib-d4 (E7080-d4) 是氘标记的 Lenvatinib。 Lenvatinib (E7080) 是一种口服的多靶点酪氨酸激酶抑制剂,可抑制 VEGFR1-3、FGFR1-4、PDGFR、KIT 和 RET,显示出有效的抗肿瘤活性。 | ||||
| GC45828 | Ponatinib-d8 | 1562993-37-6 | >99.00% | |
An internal standard for the quantification of ponatinib | ||||
| GC46924 | BIBF 1120-13C-d3 | - | >99.00% | |
A neuropeptide with diverse biological activities | ||||
| GC48118 | Sunitinib-d10 | 1126721-82-1 | >99.00% | |
An internal standard for the quantification of sunitinib | ||||
| GC49686 | N-desmethyl Regorafenib N-oxide | 835621-12-0 | >90.00% | |
An active metabolite of regorafenib | ||||
| GC49700 | Takeda-6d | 1125632-93-0 | >95.00% | |
A dual inhibitor of RAF kinases and VEGFR2 | ||||
| GC50028 | ZM 306416 hydrochloride | 196603-47-1 | - | |
A VEGF receptor kinase inhibitor | ||||
| GC50233 | Vatalanib succinate | 212142-18-2 | - | |
Potent VEGFR inhibitor; also aromatase inhibitor | ||||
| GC50330 | BMS 605541 | 639858-32-5 | - | |
Potent VEGFR-2 inhibitor | ||||
| GC60283 | Pentagamavunon-1 | 27060-70-4 | >99.50% | |
Pentagamavunon-1 (PGV-1) 是Curcumin 的类似物,具有口服活性,通过多个机制诱导凋亡信号,如抑制COX-2 和 VEGF。Pentagamavunon-1 (PGV-1) 可抑制 NF-κB 的激活。 | ||||
| GC60365 | TIE-2/VEGFR-2 kinase-IN-1 | 453590-24-4 | >99.50% | |
TIE-2/VEGFR-2 kinase-IN-1 用于合成 TIE-2 或者 VEGFR-2 抑制剂,从专利 WO2003022852 中获得,例 14。TIE-2/VEGFR-2 kinase-IN-1 用于研究不适当的血管生成相关疾病。 | ||||
